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Abstract:  The present study deals with the first total synthesis of the proline-rich 
cyclopolypeptide stylisin 2 via a solution phase technique by coupling of the   
Boc-L-Pro-L-Ile-L-Pro-OH tripeptide unit with the L-Phe-L-Pro-L-Pro-L-Tyr-OMe 
tetrapeptide unit, followed by cyclization of the resulting linear heptapeptide fragment. The 
chemical structure of the finally synthesized peptide was elucidated by FTIR, 
1H/
13C-NMR 
and FAB MS spectral data, as well as elemental analyses. The newly synthesized peptide 
was subjected to antimicrobial screening against eight pathogenic microbes and found to 
exhibit potent antimicrobial activity against Pseudomonas aeruginosa, 
Klebsiella pneumoniae and Candida albicans, in addition to moderate antidermatophyte 
activity against pathogenic Trichophyton mentagrophytes and Microsporum audouinii 
when compared to standard drugs—gatifloxacin and griseofulvin. 
Keywords:  marine natural product; stylisin 2; Stylissa caribica; peptide synthesis; 
antimicrobial activity 
 
1. Introduction 
During past years, natural products derived from marine sponges have played a crucial role in the 
pharmaceutical research as biomedically useful agents or as lead compounds for drug development. 
Among them, bioactive cyclopeptides with unique structures have emerged as vital organic congeners 
which may prove better candidates to overcome the problem of widespread increase of microbial 
resistance towards conventional drugs [1]. Diverse biological activities possessed by marine   
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sponge-derived natural cyclic peptides include antimicrobial, cytotoxic, anti-HIV, nematocidal,   
anti-inflammatory, serine protease and protein tyrosine phosphatase inhibitory activity [2–8]. 
Stylisin 2, a natural cyclic heptapeptide has been isolated from the Jamaican sponge Stylissa caribica 
and its structure was elucidated on the basis of 1D and 2D NMR data (
1H, 
13C, COSY, HMQC, 
HMBC, ROESY), followed by determination of absolute configuration of amino acids by Marfey’s 
analysis [9].  
Prompted by the pharmacological properties of proline-rich cyclopeptides [10–13] as well as to 
obtain a natural bioactive peptide in good yield and in continuation of our efforts toward synthesizing 
natural cyclopeptides [14–27], the present study was aimed at the first total synthesis of stylisin 2 (8) 
using solution phase techniques. The synthesized cyclooligopeptide was also subjected to antibacterial 
and antifungal screening. 
2. Results and Discussion  
In present study, a disconnection strategy was employed to carry out the first total synthesis of 
stylisin 2. The cyclic heptapeptide molecule was split into three dipeptide units Boc-L-Pro-L-Ile-OMe (1), 
Boc-L-Phe-L-Pro-OMe (2), Boc-L-Pro-L-Tyr-OMe (3) and single amino acid unit L-Pro-OMe·HCl (4). 
The required dipeptides 1–3 were prepared by coupling of Boc-amino acids, viz. Boc-L-Pro and   
Boc-L-Phe with the corresponding amino acid methyl ester hydrochlorides viz.  L-Ile-OMe·HCl,  
L-Pro-OMe·HCl and L-Tyr-OMe·HCl employing dicyclohexylcarbodiimide (DCC) as coupling agent 
[28]. Racemization was suitably controlled during normal peptide couplings by the use of less 
strenuous conditions, i.e., low temperature, controlled quantity of the base such as triethylamine (TEA) 
and a suitable solvent like dimethylformamide (DMF) or tetrahydrofuran (THF). The ester group of 
dipeptide 1 was removed by alkaline hydrolysis with LiOH and the deprotected peptide was coupled 
with amino acid methyl ester hydrochloride 4 using diisopropylcarbodiimide (DIPC)/DCC and 
triethylamine (TEA), to get the tripeptide unit Boc-L-Pro-L-Ile-L-Pro-OMe (5). Similarly, dipeptide 2 
after deprotection at the carboxyl end, was coupled with dipeptide 3 deprotected at amino terminal, to 
get the tetrapeptide unit Boc-L-Phe-L-Pro-L-Pro-L-Tyr-OMe (6). After removal of the ester group of 
tripeptide 5 and the Boc group of tetrapeptide 6, these deprotected units were coupled to get the linear 
heptapeptide unit Boc-L-Pro-L-Ile-L-Pro-L-Phe-L-Pro-L-Pro-L-Tyr-OMe (7). The methyl ester group of 
the linear peptide fragment was replaced by a pentafluorophenyl (pfp)/p-nitrophenyl (pnp) ester group. 
The Boc-group of the resulting compound was removed using trifluoroacetic acid (TFA) and the 
deprotected linear fragment was now cyclized by keeping the whole contents at 0 °C for 7 days in the 
presence of catalytic amounts of TEA/NMM/pyridine to get cyclooligopeptide 8  (Scheme 1).  The 
cyclization of the linear peptide was indicated by the disappearance of absorption bands at 1,750, 
1,271 cm
−1 and 1,389, 1,373 cm
−1 (CO stretching of ester and CH deformation of tert-butyl group) in 
the IR spectrum of compound
  8. Formation of cyclooligopeptide was further confirmed by the 
disappearance of the singlet at δ 1.49 corresponding to the nine protons of the Boc tert-butyl group and 
the singlet at d 3.54 corresponding to the three protons of the methyl ester in the 
1H-NMR spectrum of 
compound 8. Seven signals between δ 4.39–3.85 in the proton spectrum of compound 8 agree with the 
expected peptidic structure for the compound, with these signals being attributable to the alpha protons 
of seven amino acids. The NMR data of the synthetic stylisin 2 are identical with those of the natural Mar. Drugs 2010, 8  
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product within the error range of d 0.07 (
1H) and 1 (
13C), respectively. Furthermore, the 
1H-NMR and 
13C-NMR spectra of the synthesized cycloheptapeptide showed characteristic peaks confirming the 
presence of all the 57 protons and 44 carbon atoms. The presence of a [M + H]
+ ion peak at m/z 812.9 
corresponding to the molecular formula C44H57N7O8 in the ESI-MS/MS spectrum of compound 8, 
along with other fragment ion peaks resulting from cleavage at the ‘Ile-Pro’ and ‘Phe-Pro’ amide bond 
levels, showed the exact sequence of attachment of all the seven amino acid moieties in a chain. In 
addition, elemental analysis of compound 8 afforded values (±0.03) in accordance with the molecular 
composition. Synthesis of stylisin 2 (8) was thus carried out successfully with good yield and pyridine 
was proven to be an effective base for cyclization of the linear heptapeptide fragment.  
Scheme 1. Synthetic route for natural cycloheptapeptide stylisin 2 (8). 
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Reagents and conditions: (i) LiOH, THF-H2O (1:1), RT, 1 h; (ii) TFA, CHCl3, RT, 1 h;   
(iii) DIPC/DCC, TEA, DMF/THF, RT, 24–36 h; (iv) DCC, pfp/pnp, RT, 12 h;   
(v) TEA/NMM/pyridine, CHCl3, 7 days, 0 °C. Mar. Drugs 2010, 8  
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Comparison of antimicrobial screening data (Table 1) suggested that cyclooligopeptide 8 exhibited 
higher antibacterial activity against the Gram negative bacteria Klebsiella pneumoniae and 
Pseudomonas aeruginosa, and potent antifungal activity against pathogenic Candida albicans with 
MIC values of 12.5−6 μg/mL, in comparison to a standard drug—gatifloxacin. Moreover, compound 8 
displayed a moderate level of biological activity against the dermatophytes Microsporum audouinii and 
Trichophyton mentagrophytes with MIC values of 6 μg/mL. However, compound 8 displayed no 
significant activity neither against Gram positive bacteria nor against the fungus A. niger. 
Table 1. Antimicrobial activity data for compound 7 and 8. 
Compound 
Diameter of zone of inhibition (mm) 
Bacterial strains  Fungal strains 
B.  
sub. 
S.  
aur. 
P.  
aeru. 
K.  
pneu. 
C.  
alb. 
M.  
audo.
A.  
niger 
T.  
menta.
7  10(25)
† 14(12.5) 22(6) 23(6)  21(6) 11(6)  –  14(6) 
8  13(25) 16(12.5) 26(6)  28(6)  27(6) 15(6)  –  18(6) 
Control *  –  –  –  –  –  –  –  – 
Gatifloxacin 18(12.5)  28(6) 22(6)  25(6)  –  –  –  – 
Griseofulvin –  –  – –  20(6) 17(6)  18(12.5)  20(6) 
B. sub.:  Bacillus subtilis;  S. aur.: Staphylococcus aureus; P. aeru.: Pseudomonas aeruginosa;  
K. pneu.: Klebsiella pneumoniae; C. alb.: Candida albicans; M. audo.:Microsporum audouinii;  
A. niger: Aspergillus niger; T. menta.: Trichophyton mentagrophytes. 
† Values in bracket are MIC values (μg/mL); * DMF/DMSO. 
Analysis of the antimicrobial activity data revealed that the linear heptapeptide 7 displayed less 
bioactivity against pathogenic bacteria and fungi compared to its cyclic form 8. This is because 
cyclization of peptides reduces the degree of freedom for each constituent within the ring and thus 
leads to substantially reduced flexibility, increased potency and selectivity for cyclic peptides. Further, 
the inherent flexibility of linear peptides leads to different conformations which can bind to more than 
one receptor molecules, resulting in undesirable adverse effects.  
3. Experimental  
Melting points were determined by open capillary method and are uncorrected. L-Amino acids,  
di-tert-butylpyrocarbonate (Boc2O), DCC, DIPC, TFA, TEA, pyridine and NMM were procured from 
SpectroChem Limited (Mumbai, India). IR spectra were recorded on a Shimadzu 8700 FTIR 
spectrophotometer using a thin film supported on KBr pellets or utilizing chloroform solutions.   
1H-NMR and 
13C-NMR spectra were recorded on a Bruker AC NMR spectrometer (300 MHz) using 
CDCl3 as solvent and TMS as internal standard. The mass spectra were recorded on a JMS-DX 303 
Mass spectrometer (Jeol, Tokyo, Japan) operating at 70 eV in ESI-MS/MS mode. Optical rotation of 
the synthesized peptide derivatives was measured in methanol on an automatic polarimeter in a 2 dm 
tube at 25 °C using a sodium lamp. Elemental analyses of all compounds were performed on a Vario 
EL III elemental analyzer. Purity of all synthesized compounds was checked by TLC on precoated 
silica gel G plates utilizing chloroform/methanol in different ratios (8:2/7:3, v/v) as developing solvent 
system and spots were detected by exposure to iodine vapours in a tightly closed chamber. Mar. Drugs 2010, 8  
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3.1. General procedure for the preparation of linear tri/tetrapeptide segments 
To a solution of amino acid methyl ester hydrochloride or dipeptide methyl ester (0.01 mol) in 
DMF (25 mL), TEA (0.021 mol) was added in portions at 0 °C and the reaction mixture was stirred for 
15 min, maintaining the temperature between 0−5 °C. Boc-dipeptide (0.01 mol) was dissolved in DMF 
(25 mL) and DIPC or DCC (0.01 mol) was added in portions with stirring. Stirring was first done for 
1 h at 0−5 °C and then further for 24 h at room temperature (RT). Precaution was taken not to allow 
the reaction temperature to exceed RT to avoid the risk of racemization. After the completion of the 
reaction, the reaction mixture was diluted with an equal amount of water. The precipitated solid was 
filtered, washed with water and recrystallized from a mixture of chloroform and petroleum ether   
(bp 40−60 °C) followed by cooling at 0 °C to get the title compounds.  
tert-Butyloxycarbonyl-L-prolyl-L-isoleucyl-L-proline methyl ester ( 5). Semisolid mass; Yield 87%; 
[α]D −41.4°; Rf 0.78; IR (CHCl3): v 3,122 (N–H str, amide), 2,997–2,989 (C–H str, CH2, Pro), 2,965, 
2,927 (C–H str, asym, CH3 and CH2), 2,869 (C–H str, sym, CH3), 1,752 (C=O str, ester), 1,678, 1,673, 
1,644 (C=O str, 3˚ and 2˚ amide), 1,536 (N–H bend, 2˚ amide), 1,388, 1,375 (C–H bend, tert-butyl),  
1,269 (C–O str, ester) cm
−1; 
1H-NMR (CDCl3): δ 6.25 (1H, br. s, NH), 4.52 (1H, t, J = 8.6 Hz, H-α, Ile), 
4.11 (1H, t, J = 6.9 Hz, H-α, Pro-1), 3.92 (1H, t, J = 6.9 Hz, H-α, Pro-2), 3.62 (3H, s, OCH3),  
3.41 (2H, t, J = 7.2 Hz, H-δ, Pro-2), 3.21 (2H, t, J = 7.1 Hz, H-δ, Pro-1), 2.55 (2H, q, H-β, Pro-1),  
2.04 (3H, m, H-β, Pro-2 and H-β, Ile), 1.97 (2H, m, H-γ, Pro-2), 1.90 (2H, m, H-γ, Pro-1),   
1.64 (2H, q, H-γ, Ile), 1.48 (9H, s, tert-butyl), 1.03 (3H, d, J = 5.9 Hz, H-γ′, Ile), 0.97 (3H, t, J = 7.8 Hz, 
H-δ, Ile); Anal. Calcd. for C32H37N3O6: C, 60.12; H, 8.48; N, 9.56. Found: C, 60.15; H, 8.49; N, 9.54%. 
tert-Butyloxycarbonyl-L-phenylalanyl-L-prolyl-L-prolyl-L-tyrosine methyl ester  (6). Semisolid mass; 
Yield 79%; [α]D −69.2°; Rf 0.59; IR (CHCl3): v 3,372 (O–H str, Tyr), 3,123, 3,119 (N–H str, amide), 
3,069, 3,055 (C–H str, rings), 2,999–2,987 (C–H str, CH2, Pro), 2,929, 2,925 (C–H str, asym, CH2), 
2,875, 2,852 (C–H str, sym, CH3 and CH2), 1,748 (C=O str, ester), 1,682–1,678, 1,645, 1,639 (C=O str, 
3˚ and 2˚ amide), 1,588, 1,483 (skeletal bands), 1,539, 1,532 (N–H bend, 2˚ amide), 1,389, 1,374 (C–H 
bend,  tert-butyl), 1,266 (C–O str, ester), 1,230 (C–O str, phenolic), 828, 725, 689 (C–H bend,   
out-of-plane (oop), rings) cm
−1; 
1H-NMR (CDCl3): δ 8.65 (1H, br. s, NH), 7.50 (2H, t, J = 7.2 Hz, 
4.4 Hz, H at C-3 and C-5, Phe), 6.94 (1H, t, J = 6.2 Hz, H at C-4, Phe), 6.90 (2H, d, J = 8.5 Hz,  
H at C-2 and C-6, Tyr), 6.85 (2H, d, J = 8.8 Hz, 5.4 Hz, H at C-2 and C-6, Phe), 6.79 (2H, d, J = 8.6 Hz, 
H at C-3 and C-5, Tyr), 6.44 (1H, br. s, NH), 5.95 (1H, br. s, OH), 5.06 (1H, q, J = 7.9 Hz, H-α, Tyr), 
4.60 (1H, q, J = 5.5 Hz, H-α, Phe), 4.55 (1H, t, J = 6.9 Hz, H-α, Pro-1), 4.39 (1H, t, J = 6.9 Hz, H-α, 
Pro-2), 3.68 (4H, m, H-δ, Pro-1 and Pro-2), 3.53 (3H, s, OCH3), 2.99 (4H, m, H-β, Phe and Tyr),  
2.67 (4H, m, H-β, Pro-1 and Pro-2), 1.92 (4H, m, H-γ, Pro-1 and Pro-2), 1.55 (9H, s, tert-butyl); Anal. 
Calcd. for C34H44N4O8: C, 64.14; H, 6.96; N, 8.80. Found: C, 64.15; H, 6.99; N, 8.79%. 
3.2. Deprotection of tripeptide unit at the carboxyl terminal  
To a solution of the tripeptide 5 (4.4 g, 0.01 mol) in THF-H2O (1:1, 36 mL), 0.36 g (0.015 mol) of 
LiOH was added at 0 °C. The mixture was stirred at room temperature for 1 h and then acidified to 
pH 3.5 with 1 N H2SO4. The aqueous layer was extracted with Et2O (3 × 25 mL). The combined Mar. Drugs 2010, 8  
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organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
crude product was finally crystallized from methanol and ether to afford pure deprotected compound. 
3.3. Deprotection of tetrapeptide unit at amino terminal 
Tetrapeptide 6 (6.36 g, 0.01 mol) was dissolved in CHCl3 (15 mL) and treated with CF3COOH 
(2.28 g, 0.02 mol). The resulting solution was stirred at room temperature for 1 h, washed with 
saturated NaHCO3 solution (25 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by crystallization from CHCl3 
and petroleum ether (bp 40–60 °C) to give the pure deprotected tetrapeptide unit.  
3.4. Procedure for the synthesis of the linear heptapeptide unit 
Deprotected tetrapeptide (5.36 g, 0.01 mol) was dissolved in tetrahydrofuran (THF, 35 mL). To this 
solution, TEA (2.8 mL, 0.021 mol) was added in portions at 0 °C and the resulting mixture was stirred 
for 15 min. Deprotected tripeptide (4.25 g, 0.01 mol) was dissolved in THF (35 mL) and DIPC (1.26 g, 
0.01 mol) was added in portions to the above mixture with stirring, maintaining the temperature 
between 0−10  °C. Stirring was continued at room temperature for 36 h, after which the reaction 
mixture was filtered and the filtrate was washed with 5% NaHCO3 and saturated NaCl solutions 
(30 mL each). The organic layer was dried over anhydrous Na2SO4, filtered and evaporated in vacuum. 
The crude product was recrystallized from a mixture of chloroform and petroleum ether (bp 40−60 °C) 
followed by cooling at 0 °C.  
tert-Butyloxycarbonyl-L-prolyl-L-isoleucyl-L-prolyl-L-phenylalanyl-L-prolyl-L-prolyl-L-tyrosine methyl 
ester (7). Semisolid mass; Yield 83%; [α]D −52.7°; Rf 0.85; IR (CHCl3): v 3,375 (O–H str, Tyr), 
3,128–3,123 (N–H str, amide), 3,065 (C–H str, ring), 2,999–2,986 (C–H str, CH2, Pro), 2,968–2,963, 
2,927–2,922 (C–H str, asym, CH3 and CH2), 2,876–2,872, 2,858–2,853 (C–H str, sym, CH3 and CH2), 
1,750 (C=O str, ester), 1,679–1,673, 1,645 (C=O str, 3˚ and 2˚ amide), 1,589, 1,482 (skeletal bands), 
1539, 1,534 (N–H bend, 2˚ amide), 1,389, 1,373 (C–H bend, tert-butyl), 1,271 (C–O str, ester),   
1,233 (C–O str, phenolic), 829, 722, 687 (C–H bend, out-of-plane (oop), rings) cm
−1; 
1H-NMR 
(CDCl3): δ 9.85 (1H, br. s, NH), 8.62 (1H, br. s, NH), 7.17 (2H, dd, J = 7.2 Hz, 4.4 Hz, H at C-3 and 
C-5, Phe), 7.01 (1H, t, J = 6.2 Hz, H at C-4, Phe), 6.89, 6.81 (2H each, A2B2, J = 8.5 Hz, H at C-2, 6, 3 
and 5, Tyr), 6.84 (2H, dd, J = 8.7 Hz, 5.3 Hz, H at C-2 and C-6, Phe), 6.25 (1H, br. s, NH), 5.97 (1H, 
br. s, OH), 5.11 (1H, m, H-α, Phe), 5.04 (1H, q, H-α, Tyr), 4.38 (1H, t, J = 6.9 Hz, H-α, Pro-2),  
4.33 (1H, t, J = 8.6 Hz, H-α, Ile), 4.16 (1H, t, J = 6.9 Hz, H-α, Pro-1), 4.09 (2H, m, H-α, Pro-1 and 
Pro-2), 3.66 (2H, t, J = 7.1 Hz, H-δ, Pro-4), 3.54 (3H, s, OCH3), 3.33 (4H, m, H-δ, Pro-2 and Pro-3),  
3.21 (2H, t, J = 7.2 Hz, H-δ, Pro-1), 3.01 (4H, m, H-β, Phe and Tyr), 2.68 (6H, m, H-β, Pro-2, Pro-3 
and Pro-4), 2.54 (2H, q, H-β, Pro-1), 2.04 (1H, m, H-β, Ile), 1.92 (8H, m, H-δ, Pro-1-4), 1.64 (2H, m, 
H-γ, Ile), 1.49 (9H, s, tert-butyl), 1.00 (3H, d, J = 5.9 Hz, H-γ′, Ile), 0.96 (3H, t, J = 7.8 Hz, H-δ, Ile); 
Anal. Calcd. for C50H69N7O11: C, 63.61; H, 7.37; N, 10.38. Found: C, 63.60; H, 7.39; N, 10.40%. Mar. Drugs 2010, 8  
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3.5. Synthesis of the cyclic heptapeptide 8 
To synthesize stylisin 2 (8), linear heptapeptide unit 7 (4.72 g, 0.005 mol)  was deprotected at 
carboxyl end using LiOH (0.18 g, 0.0075 mol) to get Boc-L-prolyl-L-isoleucyl-L-prolyl-L-
phenylalanyl-L-prolyl-L-prolyl-L-tyrosine-OH. The deprotected heptapeptide unit (4.65 g, 0.005 mol) 
was now dissolved in CHCl3 (50 mL) at 0 °C. To this solution, p-nitrophenol or pentafluorophenol 
(0.94 g or 1.23 g, 0.0067 mol) and DIPC (0.63 g, 0.005 mol) were added and the mixture was stirred at 
room temperature for 12 h. The reaction mixture was filtered and the filtrate was washed with 10% 
NaHCO3 solution (3 × 25 mL) and finally washed with 5% HCl (2 × 30 mL) to get the corresponding 
p-nitro-phenyl or pentafluorophenyl ester Boc-L-prolyl-L-isoleucyl-L-prolyl-L-phenylalanyl-L-prolyl-L-
prolyl-L-tyrosine-Opnp or Boc-L-prolyl-L-isoleucyl-L-prolyl-L-phenylalanyl-L-prolyl-L-prolyl-L-tyrosine-
Opfp. To this compound (4.2 g or 4.38 g, 0.004 mol) dissolved in CHCl3 (35 mL), CF3COOH (0.91 g, 
0.008 mol) was added, stirred at room temperature for 1 h and washed with 10% NaHCO3 solution  
(2 × 25 mL). The organic layer was dried over anhydrous Na2SO4 to get L-prolyl-L-isoleucyl-L-prolyl-L-
phenylalanyl-L-prolyl-L-prolyl-L-tyrosine-Opnp or L-prolyl-L-isoleucyl-L-prolyl-L-phenylalanyl-L-prolyl-
L-prolyl-L-tyrosine-Opfp, which was dissolved in CHCl3 (25 mL) and TEA/NMM/pyridine (2.8 mL or 
2.21 mL or 1.61 mL, 0.021 mol) was added. Then, above alkaline solution was kept at 0 °C for 7 days. 
The reaction mixture was washed with 10% NaHCO3 (3 × 25 mL) and 5% HCl (2 × 30 mL) solutions. 
The organic layer was dried over anhydrous Na2SO4 and crude cyclized product was crystallized from 
CHCl3/n-hexane to get pure cyclic product 8.  
Cyclo(L-prolyl-L-isoleucyl-L-prolyl-L-phenylalanyl-L-prolyl-L-prolyl-L-tyrosinyl)  (8). White solid; 
Yield 89% (3.61 g, C5H5N), 82% (3.33 g, NMM), 79% (3.21 g, TEA); mp 216 °C (dec); [α]D −39.8° 
(c 0.2, MeOH) (−39.9 for natural stylisin 2); Rf 0.68 (CHCl3:AcOH:H2O, 3:2:5); IR (KBr): v 3,377 
(O–H str, Tyr), 3,129, 3,125-3,121 (N–H str, amide), 3,069–3,066 (C–H str, ring), 2,998–2,985   
(C–H str, CH2, Pro), 2,969–2,965, 2,929, 2,925 (C–H str, asym, CH3 and CH2), 2,875–2,872,   
2,859–2,855 (C–H str, sym, CH3 and CH2), 1,676–1,672, 1,645–1,640 (C=O str, 3˚ and 2˚ amide), 
1,587, 1,480 (skeletal bands), 1,537, 1,533–1,530 (N–H bend, 2˚ amide), 1,236 (C–O str, phenolic), 
828, 720, 689 (C–H bend, out-of-plane (oop), rings) cm
−1; 
1H-NMR (CDCl3): δ 9.75 (1H, br. s, NH), 
9.72 (1H, br. s, NH), 8.52 (1H, br. s, NH), 7.18 (2H, dd, J = 7.2 Hz, 4.4 Hz, H at C-3 and C-5, Phe), 
7.03 (1H, t, J = 6.2 Hz, H at C-4, Phe), 6.97, 6.90 (2H each, A2B2, J = 8.5 Hz, H at C-2, 6, 3 and 5, 
Tyr), 6.85 (2H, d, J = 8.6 Hz, 5.4 Hz, H at C-2 and C-6, Phe), 5.95 (1H, br. s, OH), 4.39 (2H, m, H-α, 
Phe and Tyr), 4.25 (1H, t, J = 7.0 Hz, H-α, Pro-4), 4.21 (1H, t, J = 6.9 Hz, H-α, Pro-3), 3.91 (2H, m, 
H-α, Pro-1 and Pro-2), 3.85 (1H, t, J = 8.6 Hz, H-α, Ile), 3.60 (2H, t, J = 7.2 Hz, H-δ, Pro-4), 3.26 (6H, 
m, H-δ, Pro-1−3), 2.67 (8H, m, H-β, Pro-1−4), 2.61 (4H, m, H-β, Phe and Tyr), 1.83 (8H, m, H-δ,  
Pro-1−4), 1.61 (2H, m, H-γ, Ile), 1.55 (1H, m, H-β, Ile), 1.00 (3H, d, J = 5.9 Hz, H-γ′, Ile), 0.95 (3H, t,  
J = 7.8 Hz, H-δ, Ile); 
13C-NMR (CDCl3): δ 173.5 (C=O, Ile), 172.8, 171.6 (2C, C=O, Pro-2 and Pro-4), 
170.9 (C=O, Pro-1), 170.3, 169.9 (2C, C=O, Phe and Tyr), 169.3 (C=O, Pro-3), 153.9 (C-p, Tyr), 
138.5, 133.4 (2C, C-γ, Phe and Tyr), 132.1 (2C, C-o, Phe), 129.5 (2C, C-o, Tyr), 128.9 (2C, C-m, Phe), 
128.3 (2C, C-m, Tyr), 128.0 (C-p, Phe), 58.7 (2C, C-α, Pro-1 and Pro-2), 57.3, 55.7 (2C, C-α, Pro-4 
and Pro-3), 54.3 (C-α, Ile), 53.6, 52.8 (2C, C-α, Phe and Tyr), 48.9, 48.2 (2C, C-δ, Pro-1 and Pro-3), 
46.6, 45.8 (2C, C-δ, Pro-2 and Pro-4), 43.2 (C-β, Tyr), 37.8 (C-β, Phe), 35.6 (C-β, Ile), 34.4, 33.9  
(2C, C-β, Pro-1 and Pro-4), 32.2, 30.5 (2C, C-β, Pro-2 and Pro-3), 24.8, 23.6 (2C, C-γ, Ile and Pro-3), Mar. Drugs 2010, 8  
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23.2, 22.6, 21.7 (3C, C-γ, Pro-1, Pro-2 and Pro-4), 16.2 (C-γ′, Ile), 10.3 (C-δ, Ile); ESI-MS/MS m/z 
[RI]: 812.9 [(M + 1)
+, 100], 784.9 [(812.9 − CO)
+, 14], 699.8 [(H-Pro-Phe-Pro-Pro-Tyr-Pro)
+, 37], 671.8 
[(699.8 − CO)
+, 11], 665.8 [(H-Pro-Pro-Tyr-Pro-Ile-Pro)
+, 29], 602.7 [(H-Pro-Phe-Pro-Pro-Tyr)
+, 64], 
574.7 [(602.7 − CO)
+, 19], 455.5 [(H-Pro-Pro-Tyr-Pro)
+, 38], 439.5 [(H-Pro-Phe-Pro-Pro)
+, 49], 411.5 
[(439.5 − CO)
+, 21], 358.4 [(H-Pro-Pro-Tyr)
+, 66], 342.4 [(H-Pro-Phe-Pro)
+, 32], 330.4 [(358.4 − CO)
+, 
11], 245.3 [(H-Pro-Phe)
+, 25], 217.2 [(245.3 − CO)
+, 11], 195.2 [(H-Pro-Pro)
+, 17], 136.1 [Tyr 
(C8H10NO)
+, 14], 120.1 [Phe (C8H10N)
+, 10], 107.1 [(C7H7O)
+, 12], 98.1 [(Pro)
+, 15], 93.1 [(C6H5O)
+, 
9], 91.1 [(C7H7)
+, 11], 86.1 [Ile (C5H12N)
+, 12], 77.1 [(C6H5)
+, 7], 70.1 [H-Pro (C4H8N)
+, 23], Ile: 57.1 
[(C4H9)
+, 6], 29.1 [(C2H5)
+, 9], 15.0 [(CH3)
+, 13]; Anal. Calcd. for C44H57N7O8: C, 65.09; H, 7.08; N, 
12.08. Found: C, 65.11; H, 7.05; N, 12.10%. 
3.6. Biological activity studies 
3.6.1. Antibacterial screening 
Newly synthesized linear and cyclic heptapeptides 7 and 8 were evaluated for their antibacterial 
potential against two Gram-positive bacteria—Bacillus subtilis and Staphylococcus aureus—and two 
Gram-negative bacteria—Pseudomonas aeruginosa and Klebsiella pneumonia—at concentrations of 
50−6.25 μg/mL by using a modified Kirby-Bauer disc diffusion method [29]. MIC values of the test 
compounds were determined by the Tube Dilution Technique. Both linear and cyclic heptapeptides 
were dissolved separately using DMF to prepare a stock solution of 1 mg/mL. Stock solution was 
aseptically transferred and suitably diluted with sterile broth medium to contain seven different 
concentrations of each test compound ranging from 200−3.1 μg/mL in different test tubes. All the 
tubes were inoculated with one loopful of one of the test bacteria. The process was repeated with 
different test bacteria and different samples. Tubes inoculated with bacterial cultures were incubated at 
37 °C for 18 h and the presence/absence of growth of the bacteria was observed. From these results, 
MIC of each test compound was determined against each test bacterium. A possible spore suspension 
was prepared in sterile distilled water from 5 days old culture of the test bacteria growing on nutrient 
broth media. About 20 mL of the growth medium was transferred into sterilized Petri plates and 
inoculated with 1.5 mL of spore suspension (spore concentration ~6 × 10
4 spores/mL). Filter paper 
disks of 6 mm diameter and 1 mm thickness were sterilized by autoclaving at 121 °C (15 psi) for 
15 min. Each Petri plate was divided into five equal portions along the diameter to place one disc. 
Three discs of test sample were placed on three portions together with one disc with reference   
drug—gatifloxacin and a disk impregnated with the solvent (DMF) as negative control. The Petri 
plates inoculated with bacterial cultures were incubated at 37 °C for 18 h. Diameters of the inhibition 
zones (in mm) were measured and the average diameters for test sample were calculated in triplicate. 
The diameters obtained for the test sample were compared with that produced by the standard drug. 
The results of antibacterial studies are presented in Table 1. 
3.6.2. Antifungal screening 
Serial plate dilution method was used for the evaluation of antifungal activity against the 
diamorphic fungal strain C. albicans and three other fungal strains, including A. niger and two Mar. Drugs 2010, 8  
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cutaneous fungal strains, M. audouinii and T. mentagrophytes, at concentrations of 50−6.25 μg/mL 
[30]. MIC values of the test compounds were determined by employing the same technique as used for 
antibacterial studies using DMSO instead of DMF and tubes inoculated with fungal cultures were 
incubated at 37 °C for 48 h. After incubation, the presence/absence of fungal growth was observed and 
MIC of test compounds was determined against each test fungus. A spore suspension in normal saline 
(0.91% w/v of NaCl) was prepared from culture of the test fungi on Sabouraud’s broth media. After 
transferring growth medium, Petri plates were inoculated with spore suspension. After drying, wells 
were made using an agar punch and test samples, reference drug—griseofulvin and negative control 
(DMSO) were placed in labeled wells in each Petri plate. The Petri plates inoculated with fungal 
cultures were incubated at 37 °C for 48 h. Antifungal activity was determined by measuring the 
diameter of the inhibition zone for triplicate sets. Activity of each compound was compared with 
reference standard. The results of antifungal studies are given in the Table 1. 
4. Conclusions 
The first total synthesis of the natural peptide stylisin 2 (8) was accomplished in good yield via 
coupling reactions utilizing different carbodiimides. Diisopropylcarbodiimide (DIPC)/TEA coupling 
method proved to be yield-effective, in comparison to methods utilizing DCC/TEA or NMM, 
providing 10–12% better yield. A pentafluorophenyl ester proved to be better for the activation of the 
acid functionality of the linear heptapeptide unit when compared to p-nitrophenol. Pyridine was found 
to be a good base for intramolecular cyclization of the linear peptide fragment in comparison to TEA 
and NMM. The synthesized cycloheptapeptide displayed high antibacterial activity against 
K. pneumoniae  and  P. aeruginosa, along with potent antifungal activity against C. albicans. In 
comparison, Gram negative bacteria were found to be more sensitive than Gram positive bacteria 
towards the newly synthesized peptide. On passing toxicity tests, synthesized cyclooligopeptide 8 may 
prove good candidate for clinical studies and can be new antimicrobial drug of future. 
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